Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now later-stage tilt small index

Withdrawal Symptoms: later-stage trial registry

1 of 2 indexed Withdrawal Symptoms trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count

Withdrawal Symptoms: 2 US clinical trials tracked, 1 recruiting.

Withdrawal Symptoms is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Arizona State University, running 1 of these trials.

Enrollment posture brief

Registry condition withdrawal-symptoms

OPEN 1 | RECR 50% | LATE 2 | EARLY 0 | RANK #7188 | SPON 1

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Withdrawal Symptoms (this)50%
Open-enrollment share among volume-matched conditions near Withdrawal Symptoms

Withdrawal Symptoms lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Withdrawal Symptoms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Withdrawal Symptoms is recruiting above its size-band peers.

    1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 31Phase 41

Phase Distribution

PhaseTrial count
Phase 3 1
Phase 4 1

Top Sponsors

Named interventions

Most-linked intervention names on Withdrawal Symptoms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

0.0mg placebo Varenicline b.i.d. Drug
1 trials
0.5mg Varenicline b.i.d. Drug
1 trials
1.0mg Varenicline b.i.d. Drug
1 trials
[F-18]Fallypride Drug
1 trials
Transcutaneous Cervical Vagal Nerve Stimulation Device
1 trials
Sham Stimulation Device
1 trials

US sites by state

Facility locations filed on Withdrawal Symptoms trials. A trial with sites in several states counts in each.

Georgia 1 trials
California 1 trials
Arizona 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Withdrawal Symptoms page

2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Withdrawal Symptoms condition card totals 2 registered trials; most-linked intervention 0.0mg placebo Varenicline b.i.d.; top US site state Georgia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.